Showing results (61-70 of 191) with videos related to

Sort By:
Pageof 20
Cancer Chemotherapy and Pharmacology|April 18, 2019
A single-arm phase II trial of weekly nanoparticle albumin-bound paclitaxel (nab-paclitaxel) monotherapy after standard of chemotherapy for previously treated advanced non-small cell lung cancerYasuhiro Kato, Yusuke Okuma, Kageaki Watanabe, et al.
Frontiers in Oncology|February 3, 2022
Cisplatin and Irinotecan as First-Line Chemotherapy for Previously Untreated Metastatic Thymic Carcinoma: Updated AnalysisAkito Fukuda, Yusuke Okuma, Taiki Hakozaki, et al.
Lung Cancer (Amsterdam, Netherlands)|October 19, 2010
S-1 is an active anticancer agent for advanced thymic carcinomaYusuke Okuma, Tsuneo Shimokawa, Yusuke Takagi, et al.
Molecular and Clinical Oncology|December 2, 2015
Neurotoxicity due to prophylactic cranial irradiation for small-cell lung cancer: A retrospective analysisYoshiro Nakahara, Yusuke Takagi, Yusuke Okuma, et al.
Plos One|April 5, 2013
Eligibility for bevacizumab as an independent prognostic factor for patients with advanced non-squamous non-small cell lung cancer: a retrospective cohort studyYusuke Takagi, Akira Toriihara, Yoshiro Nakahara, et al.
BMC Cancer|June 3, 2014
Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer CenterYusuke Okuma, Yukio Hosomi, Kageaki Watanabe, et al.
Case Reports in Oncology|June 1, 2017
Pneumothorax during Pazopanib Treatment in Patients with Soft-Tissue Sarcoma: Two Case Reports and a Review of the LiteratureYoshiro Nakahara, Tomoya Fukui, Ken Katono, et al.
Lung Cancer (Amsterdam, Netherlands)|January 15, 2013
Clinical outcomes with chemotherapy for advanced thymic carcinomaYusuke Okuma, Yukio Hosomi, Yusuke Takagi, et al.
Cancer Chemotherapy and Pharmacology|June 25, 2016
A phase II study of nanoparticle albumin-bound paclitaxel plus carboplatin as the first-line therapy in elderly patients with previously untreated advanced non-small cell lung cancerYusuke Okuma, Yukio Hosomi, Satoshi Takahashi, et al.
Anticancer Research|November 14, 2013
Clinical outcomes after first-line EGFR inhibitor treatment for patients with NSCLC, EGFR mutation, and poor performance statusYusuke Okuma, Yukio Hosomi, Makoto Nagamata, et al.
Pageof 20